NMC Health (NMC) Stock Rating Lowered by JPMorgan Chase & Co.

NMC Health (LON:NMC) was downgraded by JPMorgan Chase & Co. to a “neutral” rating in a report released on Wednesday. They presently have a GBX 3,270 ($44.34) target price on the stock, up from their previous target price of GBX 2,730 ($37.02). JPMorgan Chase & Co.’s price objective suggests a potential downside of 2.68% from the company’s current price.

Other research analysts also recently issued reports about the company. Berenberg Bank began coverage on NMC Health in a research note on Friday, October 6th. They set a “buy” rating and a GBX 4,000 ($54.24) price objective for the company. Jefferies Group reiterated a “hold” rating and set a GBX 3,085 ($41.84) price objective on shares of NMC Health in a research note on Wednesday, January 17th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of GBX 3,196.25 ($43.34).

NMC Health (LON:NMC) traded down GBX 20 ($0.27) during trading on Wednesday, hitting GBX 3,360 ($45.57). The company’s stock had a trading volume of 499,823 shares, compared to its average volume of 281,724. The company has a market cap of $6,920.00 and a P/E ratio of 6,000.00. NMC Health has a 1-year low of GBX 1,620 ($21.97) and a 1-year high of GBX 3,540 ($48.01).

In other NMC Health news, insider Patrick James Meade (Lord Clanwilliam) purchased 1,160 shares of the stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average cost of GBX 2,805 ($38.04) per share, with a total value of £32,538 ($44,125.31). Also, insider Jonathan Bomford purchased 1,000 shares of the stock in a transaction that occurred on Monday, November 27th. The stock was acquired at an average cost of GBX 2,877 ($39.02) per share, for a total transaction of £28,770 ($39,015.46). Over the last quarter, insiders have purchased 29,160 shares of company stock valued at $84,808,800.

TRADEMARK VIOLATION NOTICE: “NMC Health (NMC) Stock Rating Lowered by JPMorgan Chase & Co.” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/28/nmc-health-nmc-stock-rating-lowered-by-jpmorgan-chase-co.html.

NMC Health Company Profile

NMC Health plc is a private healthcare services provider in the United Arab Emirates. The Company operates through two segments: healthcare and distribution & services. The healthcare segment is engaged in providing professional medical services, comprising diagnostic services, in and outpatient clinics, provision of all types of research and medical services in the field of gynecology, obstetrics and human reproduction and retailing of pharmaceutical goods.

Analyst Recommendations for NMC Health (LON:NMC)

Receive News & Ratings for NMC Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NMC Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply